de la Fouchardière, Christelle
Fugazzola, Laura
Locati, Laura D.
Alvarez, Clara V.
Peeters, Robin P.
Camacho, Pilar
Simon, Iris M.
Jarząb, Barbara
Netea-Maier, Romana http://orcid.org/0000-0002-9603-0460
Article History
Received: 20 September 2023
Accepted: 10 November 2023
First Online: 25 November 2023
Compliance with ethical standards
:
: C.DL.F. is consultant/advisor for Amgen, Astellas Pharma, Bristol-Myers Squibb, Eisai, Eli Lilly and Company, Daichi-Sankyo, Ipsen, MSD Oncology, Pierre Fabre, Roche/Genentech and Servier; has received research funding by MSD, Natera, Pierre Fabre and Servier; has received travel/accommodation expenses by Amgen, MSD Oncology, Pierre Fabre, Roche and Servier. L.D.L. is the Chief of the European Organisation for Research and Treatment of Cancer (EORTC) Endocrine Task Force, member of ESMO, AIOM, ITOG, ITCO, AIOCC, EORTC EnTF and H&N Group; has participated in developing ESMO Thyroid cancers guideline, AIOM Thyroid cancers guideline and ESMO Salivary gland cancers guidelines; she reports speaker and consultant fees from Bayer, Eisai, Eli Lilly and Company, Ipsen, Istituto Gentili Srl, Merck Serono, MSD, NewBridge Pharmaceuticals, Roche, Sanofi and Sun Pharmaceutical Industries Ltd; has received institutional funding by Eisai and Merck and Company. L.F. is President Elect of the European Thyroid Association (ETA) and reports consultant fees from Eisai, Ipsen and Eli Lilly and Company. C.V.A. has no commercial conflicts of interest in this manuscript; she is Secretary of the Thyroid Cancer group of the ETA; member of EORTC and ESE-ETEC Endocrine Cancer Task force. R.P.P. is the Leader of the European Reference Network on Rare Adult Cancers (EURACAN) Endocrine Domain. B.J and R.N-M have no conflict of interest regarding this manuscript. P.C. and I.M.S. are employees and stock holders of Eli Lilly and Company.